pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Coronary Disease in 1 studies
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gergs, U | 1 |
| Boknik, P | 1 |
| Schmitz, W | 1 |
| Simm, A | 1 |
| Silber, RE | 1 |
| Neumann, J | 1 |
1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Coronary Disease
| Article | Year |
|---|---|
A positive inotropic effect of ATP in the human cardiac atrium.
Topics: Adenosine A1 Receptor Antagonists; Adenosine Triphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyc | 2008 |